IP Library Granted Patent US 12,582,820
Granted Patent B2
US 12,582,820 · App. 19/002,188 · Granted Mar 24, 2026

Neurostimulation therapy for treating uterine bleeding

Inventors: Alejandro Covalin (Los Angeles, CA); Christopher Czura (Oyster Bay, NY); Navid Khodaparast (Dallas, TX)
Assignee: SPARK BIOMEDICAL, INC.
A61N1/36021A61N1/0456A61N1/0551A61N1/36017
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,582,820
App. No.
19/002,188
Granted
Mar 24, 2026
Kind
B2
Abstract

In an illustrative embodiment, methods and systems for treating uterine bleeding include applying, at least every other day in which a subject exhibits or is expected to exhibit menstrual bleeding, neurostimulation therapy in one or more sessions, each session having a duration of at least five minutes, the neurostimulation therapy including applying electrical neurostimulation or mechanical neurostimulation to directly and/or indirectly activate one or more neural targets, the one or more neural targets including a trigeminal cervical complex and/or vagal efferent fibers. The neurostimulation therapy may be configured to enhance platelet function of the subject, thereby reducing a total volume of blood loss over a course of the menstrual bleeding.

Claims (23)

1 . A method for treating uterine bleeding, the method comprising:

applying, at least once within each forty-eight-hour period of a plurality of consecutive forty-eight-hour periods in which a subject exhibits or is expected to exhibit menstrual bleeding, neurostimulation therapy in one or more sessions, each session of the one or more sessions having a duration of at least five minutes, the neurostimulation therapy being configured to treat uterine bleeding in the subject, wherein

applying the neurostimulation therapy comprises applying electrical neurostimulation or mechanical neurostimulation to directly and/or indirectly activate one or more neural targets, the one or more neural targets including at least one of a trigeminal cervical complex (TCC) or vagal efferent fibers (VEF), and

the neurostimulation therapy is configured to enhance platelet function of the subject, thereby reducing a total volume of blood loss over a course of the menstrual bleeding wherein

enhancing platelet function comprises increasing a baseline ionized calcium concentration in platelets of the subject.

2 . The method of claim 1 , wherein the subject is diagnosed with abnormal uterine bleeding or heavy menstrual bleeding.

3 . The method of claim 2 , wherein the subject is diagnosed with a bleeding disorder.

4 . The method of claim 1 , wherein the neurostimulation therapy is applied at one or more regions of skin of the subject.

5 . The method of claim 4 , wherein the one or more regions of the skin of the subject are disposed on at least one of a head or a neck of the subject.

6 . The method of claim 5 , further comprising donning a head-mounted stimulation device, thereby positioning, against each skin region of the one or more regions of skin, a respective stimulation delivery element of one or more stimulation delivery elements.

7 . The method of claim 6 , wherein the head-mounted stimulation device is an ear-mounted stimulation device.

8 . The method of claim 4 , wherein applying the electrical neurostimulation at the one or more regions of the skin of the subject comprises applying the electrical neurostimulation via one or more electrodes, each electrode physically contacting a respective region of skin of the one or more regions of skin of the subject.

9 . The method of claim 8 , wherein the one or more electrodes are percutaneous electrodes.

10 . The method of claim 1 , wherein the neurostimulation therapy is applied via one or more implanted electrodes.

11 . The method of claim 1 , wherein indirectly activating the VEF comprises positioning at least one electrical or mechanical stimulation element within neurostimulation delivery range of an auricular branch of a vagus nerve (ABVN) of the subject.

12 . The method of claim 1 , wherein indirectly activating the TCC comprises positioning at least one electrical or mechanical stimulation element within neurostimulation delivery range of an auriculotemporal nerve (ATN) of the subject.

13 . The method of claim 1 , wherein the neurostimulation therapy is further configured to generate a vasodilation response in a uterus of the subject, thereby reducing at least one of dysmenorrhea or menstrual cramping.

14 . The method of claim 1 , wherein the neurostimulation therapy is further configured to activate a Nucleus Tractus Solitari (NTS) via stimulation of vagal and/or trigeminal branches to trigger release of endorphins, thereby modulating pain signals in a central nervous system (CNS) and mitigating pain in the subject.

15 . The method of claim 1 , further comprising, during a luteal phase of menses, for each respective pre-menstrual session of at least one pre-menstrual session per respective forty-eight hour timeframe of one or more consecutive forty-eight hour timeframes, applying, for a pre-menstrual session length of the respective pre-menstrual session of at least five minutes, the neurostimulation therapy for treating uterine bleeding, thereby preparing the subject with an initial increased baseline of circulating platelets with enhanced platelet function at onset of the uterine bleeding.

16 . The method of claim 1 , wherein the neurostimulation therapy is applied daily.

17 . The method of claim 1 , wherein the duration is at least ten minutes.

18 . The method of claim 1 , wherein the neurostimulation therapy is configured to reduce a total number of bleeding days over the course of the menstrual bleeding.

19 . The method of claim 1 , wherein the neurostimulation therapy is configured to reduce a total number of hours spent by the subject in bed rest over the course of the menstrual bleeding.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2025
From: COVALIN, ALEJANDRO; CZURA, CHRISTOPHER; KHODAPARAST, NAVID
To: SPARK BIOMEDICAL, INC.
Reel/Frame 071192/0895 →
Continuity (2)
Provisional Application 63667930 · Jul 5, 2024
Related Publication 20260007885A1 · Jan 8, 2026
References Cited (38)
US 6735476B2 · Mellen · 2004 [cited by applicant]
US 7657310B2 · Buras · 2010 [cited by applicant]
US 7711432B2 · Thimineur et al. · 2010 [cited by applicant]
US 8729129B2 · Tracey et al. · 2014 [cited by applicant]
US 9089719B2 · Simon et al. · 2015 [cited by applicant]
US 9925373B2 · Nirenberg · 2018 [cited by applicant]
US 10463854B2 · Perez · 2019 [cited by applicant]
US 10537703B2 · Tyler et al. · 2020 [cited by applicant]
US 10786666B2 · Chu et al. · 2020 [cited by applicant]
US 10912712B2 · Tracey et al. · 2021 [cited by applicant]
US 11260229B2 · Manogue · 2022 [cited by applicant]
US 20050065574A1 · Rezai · 2005 [cited by applicant]
US 20090287035A1 · Dietrich et al. · 2009 [cited by applicant]
US 20140135886A1 · Cook et al. · 2014 [cited by applicant]
US 20140206945A1 · Liao · 2014 [cited by applicant]
US 20150335876A1 · Jeffery et al. · 2015 [cited by applicant]
US 20190134390A1 · Shimada et al. · 2019 [cited by applicant]
US 20190321623A1 · Huston et al. · 2019 [cited by applicant]
US 20200094055A1 · Manogue · 2020 [cited by examiner]
US 20200238085A1 · Khodaparast et al. · 2020 [cited by applicant]
US 20210213286A1 · Covalin et al. · 2021 [cited by applicant]
US 20220192580A1 · Toth et al. · 2022 [cited by applicant]
US 20220212012A1 · Manogue · 2022 [cited by applicant]
US 20220305260A1 · Covalin et al. · 2022 [cited by applicant]
WO WO2021011165A1 · 2021 [cited by applicant]
Spark Biomedical, Inc., “Transcutaneous Auricular Neurostimulation (tAN™) to Aid in the Reduction of Symptoms Associated With Opioid Withdrawal”, Sparrow Clinical Whitepaper, Version: MKT-005-V1, 2021, 8 pages. [cited by applicant]
Bennett, John A., et al. “Acetylcholine Inhibits Platelet Activation”, The Journal of Pharmacology and Experimental Therapeutics, May 2019, 182-187. [cited by applicant]
Rosas-Ballina, Mauricio, et al., “Acetylcholine-Synthesizing T Cells Relay Neural Signals in a Vagus Nerve Circuit”, Science, Oct. 2011, 334(6052); 98-101. [cited by applicant]
Schedel, Angelika, et al., “Human Platelets Express Functional alpha7-Nicotinic Acetylcholine Receptors”, Arterioscler Thromb Vasc Biol, Apr. 2011, 928-934. [cited by applicant]
Nettle, “A New Care Pathway for Menstrual Health”, http://www.samphireneuro.com/nettle/health-care-providers, accessed Nov. 5, 2024, 16 pages. [cited by applicant]
Sara, Susan J., et al., “Orienting and Reorienting: the Locus Coeruleus Mediates Cognition Through Arousal”, Neuron 76, Oct. 2012, Elsevier Inc., 130-141. [cited by applicant]
Abbasian, Nima, et al., “Supramaximal Calcium Signaling Triggers Procoagulant Platelet Formation”, Blood Advances, Dept. of Pharmacology and Dept. of Biochemistry, Universit of Cambridge, Cambridge, UK, Jan. 2020, vol. … [cited by applicant]
Dobryakova, Ekaterina, et al., “The Dopamine Imbalance Hypothesis of Fatigue in Multiple Sclerosis and Other Neurological Disorders”, Frontiers in Neurology, Mar. 2015, vol. 6, Article 52, 1-8. [cited by applicant]
McLagan, Bailey, et al., “The Role of Transcutaneous Electrical Nerve Stimulation for Menstrual Pain Relief: a Randomized Control Trial”, Women's Health, vol. 20, 1-10; The Aurthor(s) 2024. [cited by applicant]
Steidel, Kenan, et al., “Transcutaneous Auricular Vagus Nerve Stimulation Influences Gastric Motility: a Randomized, Double-Blind Trial in Healthy Individuals”, Elsevier, Brain Stimulation, 2021, 1126-1132. [cited by applicant]
Elboim-Gabyzon, Michal, et al., “Transcutaneous Electrical Nerve Stimulation (TENS) for Primar Dysmenorrhea: an Overview”, International Journal of Women's Health, Dovepress, 2020:12, 1-10. [cited by applicant]
Bravo-Iniguez, Carlos E., et al., “Vagus nerve stimulation primes platelets and reduces bleeding in hemophilia A male mice”, Nature Communications, Jun. 2023, 12 pages. [cited by applicant]
Invitation to Pay Additional Fees and, Where Applicable, Protest Fee, received in International Application No. PCT/US2025/033989, mailed Sep. 4, 2025, 5 pages. [cited by applicant]